12 completed, 4 terminated, 2 unknown, 1 active not recruiting. 21 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 12, Terminated 4, Unknown 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 3 | 3 | Completed 3 |
Follow Chronic Fatigue Syndrome: new trials by email Literature Review of Chronic Fatigue Syndrome trials Research Report on Chronic Fatigue Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Lumbrokinase - Long Covid, Post-treatment Lyme Disease Syndrome | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 120 | 2024-10-09 | 2026-03-13 |
| Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation Pregabalin, Independent walking training, Placebo - Chronic Fatigue Syndrome, COVID-19, Long Haul | Phase 2 | Terminated | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 23 | 2023-10-24 | 2026-06-17 |
| Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome NAC 900mg/day, NAC 3600mg/day, NAC 0mg/day (Placebo) - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 95 | 2020-09-01 | 2026-06-22 |
| The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Pyridostigmine Bromide, Placebo - Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome | Phase 2 | Completed | Brigham and Women's Hospital | 45 | 2020-01-14 | 2022-11-08 |
| Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments 5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream - Vestibulodynia, Temporomandibular Disorder | Phase 2 | Completed | Duke University | 209 | 2019-11-04 | 2026-03-19 |
| The Comeback Study Preprocessed thawed donor FMT, Preprocessed thawed autologous FMT - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | University Hospital of North Norway | 80 | 2019-02-15 | 2024-02-23 |
| Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome CT38 - Myalgic Encephalomyelitis, Chronic Fatigue Syndrome | Phase 1 / Phase 2 | Completed | LUCINDA BATEMAN, MD | 17 | 2018-07-23 | 2020-05-12 |
| High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome Acupuncture, moxibustion, placebo - Chronic Fatigue Syndrome | Phase 2 | Unknown | Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust | 210 | 2016-11-01 | 2016-10-05 |
| Cytokine Inhibition in Chronic Fatigue Syndrome Patients Anakinra, Placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 50 | 2014-06-01 | 2016-05-25 |
| Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®) IodoCarb (r), Placebo - Chronic Fatigue Syndrome | Phase 1 / Phase 2 | Unknown | PharmaLundensis AB | 40 | 2013-02-01 | 2013-02-15 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
| Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Etanercept - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Terminated | Haukeland University Hospital | 4 | 2012-10-01 | 2015-12-02 |
| Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder Nutraceutical supplements, Placebo - Chronic Fatigue Syndrome | Phase 2 | Withdrawn | Columbia University | 2012-03-01 | 2015-04-13 | |
| Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome Pacing, relaxation therapy - Chronic Fatigue Syndrome | Phase 2 | Completed | Vrije Universiteit Brussel | 33 | 2011-08-01 | 2015-12-17 |
| B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Rituximab - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | Haukeland University Hospital | 29 | 2010-10-01 | 2014-09-01 |
| Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome Droxidopa - Chronic Fatigue Syndrome, Orthostatic Hypotension | Phase 2 | Terminated | Chelsea Therapeutics | 3 | 2010-07-01 | 2014-06-09 |
| B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome Rituximab - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Terminated | Haukeland University Hospital | 8 | 2010-06-01 | 2024-03-04 |
| The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial Clonidine, Lactose capsula - Chronic Fatigue Syndrome, Myalgic Encephalomyelitis | Phase 2 | Completed | Oslo University Hospital | 120 | 2010-02-01 | 2012-11-20 |
| Drug Intervention in Chronic Fatigue Syndrome Rituximab, Saline (NaCl 0,9 %) (placebo) - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Haukeland University Hospital | 30 | 2008-06-01 | 2021-05-11 |
| Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Cognitive Behavioral Therapy, Usual Care for Chronic Fatigue Syndrome (Active Control Group) - Chronic Fatigue Syndrome, Behavioral Therapy Targeted to Sleep Problems | Phase 1 / Phase 2 | Completed | Duke University | 24 | 2007-09-01 | 2013-03-01 |
Showing 20 of 21. Sign in to see all of them.
Fatigue Syndrome, Chronic (21) · Fatigue (5) · Fibromyalgia (2) · Hypotension, Orthostatic (2) · Post-Acute COVID-19 Syndrome (2) · Autonomic Nervous System Diseases (1) · Back Pain (1) · Chronic Pain (1) · Cystitis, Interstitial (1) · Endometriosis (1) · Epstein-Barr Virus Infections (1) · Herpes Simplex (1) · Irritable Bowel Syndrome (1) · Lyme Disease (1) · Memory Disorders (1)
Chronic Disease (21) · Disease Attributes (21) · Encephalomyelitis (21) · Muscular Diseases (21) · Musculoskeletal Diseases (21) · Nervous System Diseases (21) · Neuroinflammatory Diseases (21) · Neuromuscular Diseases (21) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Signs and Symptoms (6) · Infections (3) · Neurologic Manifestations (3) · Virus Diseases (3) · COVID-19 (2)
Rituximab (3) · 3,4-dihydroxyphenylserine aldolase (1) · Acupuncture Therapy (1) · Ascorbic Acid (1) · Clonidine (1) · Cognitive Behavioral Therapy (1) · Droxidopa (1) · Etanercept (1) · Interleukin 1 Receptor Antagonist Protein (1) · Moxibustion (1) · NAD (1) · Nortriptyline (1) · Phosphoserine (1) · Pregabalin (1) · Psychotherapy (1)
Haukeland University Hospital (4) · Duke University (2) · Brigham and Women's Hospital (1) · Chelsea Therapeutics (1) · Columbia University (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust (1) · Icahn School of Medicine at Mount Sinai (1) · LUCINDA BATEMAN, MD (1) · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland (1) · Oslo University Hospital (1) · PharmaLundensis AB (1) · Radboud University Medical Center (1) · Stanford University (1) · University Hospital of North Norway (1)
United States (9) · Norway (6) · Belgium (1) · China (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Olav Mella, PhD, MD (2) · Alfred E Slonim, MD (1) · Anders Luts, MD, PhD (1) · Andrea Nackley, PhD (1) · Andrew Krystal, M.D. (1) · Beata Tarnacka, Prof, Md, PhD (1) · Charles W Lapp, M.D. (1) · Daphne Kos, PhD (1) · David Putrino, PhD, PT (1) · David Systrom, MD (1) · Dikoma C. Shungu, Ph.D. (1) · Jos van der Meer, Prof, PhD, MD (1) · Jose Alegre-Martin, MD, PhD (1) · Jose G Montoya, MD (1) · Lucinda Bateman, MD (1)
PMID 26132314, PMID 22039471, PMID 22871021, PMID 23959519, PMID 24493300, PMID 25287104, PMID 25386668, PMID 26212172, PMID 26357864, PMID 26438161, PMID 27149955, PMID 28265678, PMID 28494812, PMID 29202780, PMID 29284500, PMID 33516248, PMID 34539356, PMID 35526605, PMID 36269028, PMID 38858151, PMID 39697147, PMID 40315935, PMID 42857927
R01HD096331 (1), R01NS116887 (1), R21NR010539 (1)